Electronic physician notification to facilitate the recognition and management of severe aortic stenosis: Rationale, design, and methods of the randomized controlled DETECT AS trial

被引:0
|
作者
Abou-Karam, Roukoz [1 ,2 ]
Tanguturi, Varsha [3 ]
Cheng, Fangzhou [1 ,2 ]
Elmariah, Sammy [4 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Dept Med, Boston, MA USA
[2] Broad Inst MIT & Harvard, Cardiovasc Dis Ini tiat, Cambridge, MA USA
[3] Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA USA
[4] Univ Calif San Francisco, Dept Med, Div Cardiovasc Med, 505 Parnassus Ave,room L-523, San Francisco, CA 94143 USA
关键词
VALVE-REPLACEMENT; SYMPTOMATIC PATIENTS; NATURAL-HISTORY; OUTCOMES; TRANSCATHETER; DISEASE; DISPARITIES; GRADIENT; SURGERY; SOCIETY;
D O I
10.1016/j.ahj.2024.06.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Symptomatic severe aortic stenosis causes substantial morbidity and mortality when left untreated, yet recent data suggest its undertreatment. Objective To evaluate the efficacy of electronic physician notification to facilitate the guideline-directed management of patients with severe aortic stenosis. Hypothesis We hypothesize that patients with severe aortic stenosis who are in the care of physicians who receive the notification are more likely to undergo aortic valve replacement within one year. Methods/Design The Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis (DETECT AS) trial is a randomized controlled trial and quality improvement initiative designed to evaluate the efficacy of electronic provider notification versus usual clinical care in the management of patients with severe aortic stenosis. Providers ordering an echocardiogram with findings potentially indicative of severe aortic stenosis are randomized to receive electronic notification with customized guideline recommendations for the management of severe aortic stenosis or usual care (no notification). Randomization continues until 940 patients are enrolled. Setting Multicentered, academic health system. Outcomes The primary endpoint is the proportion of patients with severe aortic stenosis receiving an aortic valve replacement within one year of the index echocardiogram. Secondary endpoints include mor tality, hear t failure hospitalization, transthoracic echocardiogram utilization, aortic stenosis billing code, and cardiology/Valve Team referral. Conclusion The DETECT AS trial will provide insight into whether electronic notification of providers on the presence of severe aortic stenosis and associated clinical guideline recommendations will facilitate recognition and guideline-directed management of severe aortic stenosis.
引用
收藏
页码:39 / 48
页数:10
相关论文
共 50 条
  • [1] Rationale and design of the Aortic Valve replAcemenT versus conservative treatment in Asymptomatic seveRe aortic stenosis (AVATAR trial): A randomized multicenter controlled event-driven trial
    Banovic, Marko
    Iung, Bernard
    Bartunek, Jozef
    Asanin, Milika
    Beleslin, Branko
    Biocina, Bojan
    Casselman, Filip
    da Costa, Mark
    Deja, Marek
    Gasparovic, Hrvoje
    Kala, Petr
    Labrousse, Lois
    Loncar, Zlatibor
    Marinkovic, Jelena
    Nedeljkovic, Ivana
    Nedeljkovic, Milan
    Nemec, Peter
    Nikolic, Serge D.
    Pencina, Michael
    Penicka, Martin
    Ristic, Arsen
    Sharif, Faisal
    Van Camp, Guy
    Vanderheyden, Marc
    Wojakowski, Wojtek
    Putnik, Svetozar
    AMERICAN HEART JOURNAL, 2016, 174 : 147 - 153
  • [2] Rationale and design of the early valve replacement in severe asymptomatic aortic stenosis trial
    Richardson, Carla
    Gilbert, Tom
    Aslam, Saadia
    Brookes, Cassandra L.
    Singh, Anvesha
    Newby, David E.
    Dweck, Marc R.
    Stewart, Ralph A. H.
    Myles, Paul S.
    Briffa, Tom
    Selvanayagam, Joseph
    Chow, Clara K.
    Murphy, Gavin J.
    Akowuah, Enoch F.
    Lord, Joanne
    Barber, Shaun
    Di Paola, Ana Suazo
    McCann, Gerry P.
    Hillis, Graham S.
    AMERICAN HEART JOURNAL, 2024, 275 : 119 - 127
  • [3] A patient advocate to facilitate access and improve communication, care, and outcomes in adults with moderate or severe asthma: Rationale, design, and methods of a randomized controlled trial
    Apter, Andrea J.
    Morales, Knashawn H.
    Han, Xiaoyan
    Perez, Luzmercy
    Huang, Jingru
    Ndicu, Grace
    Localio, Anna
    Nardi, Alyssa
    Klusaritz, Heather
    Rogers, Marisa
    Phillips, Alexis
    Cidav, Zuleyha
    Schwartz, J. Sanford
    CONTEMPORARY CLINICAL TRIALS, 2017, 56 : 34 - 45
  • [4] Management of Fluid Overload in Patients With Severe Aortic Stenosis (EASE-TAVR) A Randomized Controlled Trial
    Halavina, Kseniya
    Koschutnik, Matthias
    Dona, Carolina
    Autherith, Maximilian
    Md, Fabian Petric
    Rockel, Anna
    Spinka, Georg
    Puchinger, Juergen
    Danesh, Daryush
    Wiesholzer, Martin
    Mascherbauer, Ktharina
    Heitzinger, Gregor
    Dannenberg, Varius
    Koschatko, Sophia
    Jantsch, Charlotte
    Winter, Max-Paul
    Goliasch, Georg
    Kammerlander, Andreas A.
    Bartko, Philipp E.
    Hengstenberg, Christian
    Mascherbauer, Julia
    Nitsche, Christian
    JACC-CARDIOVASCULAR INTERVENTIONS, 2024, 17 (17) : 2054 - 2066
  • [5] Rationale and design of the randomized, controlled Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis (EVOLVED) trial
    Bing, Rong
    Everett, Russell J.
    Tuck, Christopher
    Semple, Scott
    Lewis, Steff
    Harkess, Ronnie
    Mills, Nicholas L.
    Treibel, Thomas A.
    Prasad, Sanjay
    Greenwood, John P.
    McCann, Gerry P.
    Newby, David E.
    Dweck, Marc R.
    AMERICAN HEART JOURNAL, 2019, 212 : 91 - 100
  • [6] A goal management intervention for polyarthritis patients: rationale and design of a randomized controlled trial
    Arends, Roos Y.
    Bode, Christina
    Taal, Erik
    Van de Laar, Mart A. F. J.
    BMC MUSCULOSKELETAL DISORDERS, 2013, 14
  • [7] A goal management intervention for polyarthritis patients: rationale and design of a randomized controlled trial
    Roos Y Arends
    Christina Bode
    Erik Taal
    Mart AFJ Van de Laar
    BMC Musculoskeletal Disorders, 14
  • [8] Rationale and Design of a Randomized Controlled Trial of DonorDerived Cell-Free DNA to Detect Rejection in Cardiac Transplantation (DETECT)
    Shah, P.
    Mehra, M. R.
    Colvin, M. M.
    DeVore, A. D.
    Eisen, H. J.
    Friedman, L.
    Hsich, E.
    Kim, P. J.
    Marshall, K.
    Olymbios, M.
    Patel, J.
    Schlendorf, K. H.
    Rabine, S.
    Stehlik, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (04): : S114 - S115
  • [9] TAVR in Bicuspid Aortic Stenosis Current Evidence and Proposal for a Randomized Controlled Trial Design
    Nuyens, Philippe
    De Backer, Ole
    Sathananthan, Janarthanan
    Jorgensen, Troels Hojsgaard
    Treede, Hendrik
    Leipsic, Jonathon A.
    Bax, Jeroen J.
    Webb, John G.
    Mehran, Roxana
    Chen, Mao
    Reardon, Michael
    Leon, Martin B.
    Sondergaard, Lars
    JACC-CARDIOVASCULAR INTERVENTIONS, 2023, 16 (13) : 1682 - 1687
  • [10] Rationale and design of a prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers with Aortic stenosis [RHEIA] trial)
    Eltchaninoff, Helene
    Bonaros, Nikolaos
    Prendergast, Bernard
    Nietlispach, Fabian
    Vasa-Nicotera, Mariuca
    Chieffo, Alaide
    Pibarot, Philippe
    Bramlage, Peter
    Sykorova, Lenka
    Kurucova, Jana
    Bax, Jeroen J.
    Windecker, Stephan
    Dumonteil, Nicolas
    Tchetche, Didier
    AMERICAN HEART JOURNAL, 2020, 228 : 27 - 35